EQL Pharma AB reported a strong start to its fiscal year 2025 with 29.5% revenue growth and increased EBITDA, despite a decline in net profit due to operational costs and strategic investments.

EQL Pharma AB reported a strong Q4 2024/2025 with a 28.0 million SEK increase in EBITDA, driven by revenue growth of 38.23% and a focus on targeting Nordic pharmacies and hospitals.